Organic compounds -- part of the class 532-570 series – Organic compounds – Oxygen containing
Reexamination Certificate
2008-02-13
2010-10-12
Keys, Rosalynd (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Oxygen containing
Reexamination Certificate
active
07812197
ABSTRACT:
The present invention concerns a method for the preparation of therapeutically valuable triphenylbutene derivatives, especially ospemifene or fispemifene.
REFERENCES:
patent: 4177121 (1979-12-01), Ando et al.
patent: 4656187 (1987-04-01), Black et al.
patent: 4696949 (1987-09-01), Toivola et al.
patent: 4894373 (1990-01-01), Young
patent: 4935243 (1990-06-01), Borkan et al.
patent: 4996225 (1991-02-01), Toivola et al.
patent: 5118667 (1992-06-01), Adams et al.
patent: 5189212 (1993-02-01), Ruenitz
patent: 5192525 (1993-03-01), Yang et al.
patent: 5196435 (1993-03-01), Clemens et al.
patent: 5352699 (1994-10-01), Jackson
patent: 5446203 (1995-08-01), McNelis
patent: 5470883 (1995-11-01), Stromberg
patent: 5491173 (1996-02-01), Toivola et al.
patent: 5567714 (1996-10-01), Bruns
patent: 5658931 (1997-08-01), Bryant et al.
patent: 5691355 (1997-11-01), Bryant et al.
patent: 5693674 (1997-12-01), Bitonti
patent: 5719136 (1998-02-01), Chwalisz et al.
patent: 5747059 (1998-05-01), Korsgaard et al.
patent: 5750576 (1998-05-01), DeGregorio et al.
patent: 5807899 (1998-09-01), Bohlmann et al.
patent: 5821254 (1998-10-01), Sporn et al.
patent: 5827892 (1998-10-01), Loser et al.
patent: 5852059 (1998-12-01), Thompson
patent: 5877219 (1999-03-01), Willson
patent: 5912273 (1999-06-01), DeGregorio et al.
patent: 6037379 (2000-03-01), Harkonen et al.
patent: 6245342 (2001-06-01), Golz-Berner et al.
patent: 6245352 (2001-06-01), Arbuthnot et al.
patent: 6245819 (2001-06-01), Halonen et al.
patent: 6525084 (2003-02-01), Rasmussen et al.
patent: 6576645 (2003-06-01), Sodervall et al.
patent: 6632447 (2003-10-01), Steiner et al.
patent: 6875775 (2005-04-01), Sodervall et al.
patent: 6984665 (2006-01-01), Blom et al.
patent: 2001/0034340 (2001-10-01), Pickar
patent: 2004/0248989 (2004-12-01), Santti et al.
patent: 2005/0182143 (2005-08-01), Anttila
patent: 2005/0187302 (2005-08-01), Blom
patent: 2005/0215528 (2005-09-01), Furuya et al.
patent: 2007/0104742 (2007-05-01), Lehtola et al.
patent: 2007/0197664 (2007-08-01), Steiner et al.
patent: 2007/0203180 (2007-08-01), Hoekstra et al.
patent: 0 095 875 (1983-12-01), None
patent: 0 664 124 (1995-07-01), None
patent: 0 779 808 (1999-08-01), None
patent: 0 760 651 (2001-07-01), None
patent: 1 125 582 (2001-08-01), None
patent: WO 92/06068 (1992-04-01), None
patent: WO 93/19746 (1993-10-01), None
patent: WO 95/26720 (1995-10-01), None
patent: WO 96/07402 (1996-03-01), None
patent: WO 96/35417 (1996-11-01), None
patent: WO 96/40616 (1996-12-01), None
patent: WO 97/32574 (1997-09-01), None
patent: WO 99/42427 (1999-08-01), None
patent: WO 99/63974 (1999-12-01), None
patent: WO 01/36360 (2001-05-01), None
patent: WO 01/54699 (2001-08-01), None
patent: WO 02/07718 (2002-01-01), None
patent: WO 02/090305 (2002-11-01), None
patent: WO 03/047504 (2003-06-01), None
patent: WO 03/103649 (2003-12-01), None
patent: WO 2005/079777 (2005-09-01), None
U.S. Appl. No. 12/030,415, filed Feb. 13, 2008, Marja Sodervall et al.
B.H. Mitlak et al., “Selective Estrogen Receptor Modulators,” Drugs 57(5):653-663, May 1999.
Budavari, S. et al., eds., The Merck Index. Eleventh Edition, p. 1430, No. 9019, Merck & Co., Inc., Rathway, NJ, USA (1989).
Dimaraki et al. (European Journal of Endocrinology, vol. 150, pp. 481-487; 2004).
Ferguson et al., Alkali Metal Ion Mediated Cyclization of 4,4′-(3,6-dioxaocta-1,8-diyloxy)-bis(benzophenone), Tetrahedron Letters, Jun. 1993, vol. 34, No. 23, pp. 3719-3722.
G.K. Bolhuis, K. Zuurman, G.H.P. te Wierik; Improvement of dissolution of poorly soluble drugs by solid deposition on a super disintegant. II The choice of super disintegrants and effect of granulation; European Journal of Pharmaceutical Sciences; 1997; 63-69; Elsevier Science B.V.
Goldstein, S.R. et al.; “A pharmacological review of selective oestrogen receptor modulators,” Human Reproduction Udate 6:212-224, Oxford university Press (May-Jun. 2000).
Grodstein, F. And Stampfer, M.J., “Estrogen for women at varying risk of coronary disease,” Maturitas 30:19-26, Elsevier Science Ireland Ltd. (1998).
Henderson, V.W., “Estrogen, Cognition, and a Woman's Risk of Alzheimer's Disease,” The American Journal of Medicine 103:11S-18S, Excerpta Medica, Inc. (1997).
International Search Report for International Application No. PCT/Fl100/00946, mailed Feb. 8, 2001.
Jordan, V. Craig; “Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines, 2. Clinical Considerations and New Agents,” Journal of Medicinal Chemistry, Vo. 46, No. 7, Mar. 27, 2003, pp. 1081-1111.
K.C. Baynes et al., “Selective oestrogen receptor modulators: a new paradigm for HRT,” Curr. Opin Obstet Gynecol 10(3): 189-192, Jun. 1998.
Kangas, L. et al., “A new triphenylethylene compound, Fc-1157a: II. Antitumor effects,” Cancer Chemother. Pharmacol. 17:109-113, Springer-Verlag (1986).
Kangas, L. et al., “Bioluminescence of Cellular ATP: A New Method for Evaluating Cytotoxic Agents In Vitro,” Medical Biology 62:338-343, Duodecim (1984).
Kangas, L., “Biochemical and pharmacological effects of toremifene metabolities,” Cancer Chemother. Pharmacol. 27:8-12, Springer-Verlag (Apr. 1990).
Kauffman, Raymond F., et al., “Selective Estrogen Receptor Modulators,” Drug News & Perspectives 1995 8 (9) pp. 531-539.
Khovidhunkit, W. and Shoback, D.M., “Clinical Effects of Raloxifene Hydrochloride in Women,” Ann. Intern. Med. 130:431-439, American College of Physicians (Mar. 1999). Lobo, R.A., “Benefits and risks of estrogen replacement therapy,” Am. J. Obstet. Gynecol. 173:982-989, Mosby-Year Book, Inc. (1995).
Lobo, R.A., “Benefits and risks of estogren replacement therapy,” Am. J. Obstet. Gynecol. 173:982-989, Mosby-Year Book, Inc. (1995).
M. Whitehead, “Treatments for menopausal and post-menopausal problems: present and future,” Baillieres Clin Obstet Gynaecol 10(3): 515-530, Sep. 1996 (online abstract).
M.M. Kennedy, “Tamoxifen and the endometrium: review of 102 cases and comparison with HRT-related-and non-HRT-related endometrial pathology,” Int J Gynecol Pathol 18(2): 130-137, Apr. 1999 (online abstract).
M.W. DeGregorio et al., “Hormone replacement therapy and breast cancer: revisiting the issues,” J AM Pharm Assoc. 38(6): 738-744, Nov.-Dec. 1998, (online abstract).
Macgregor, J.I. and Jordan, V.C., “Basic Guide to the Mechanisms of Antiestrogen Action,” Pharmacol. Rev. 50:151-196, Williams and Wilkins Co. (1998).
Merriam-Webster's Medical Dictionary (c) [online], Merriam-Webster, Inc., 2002 [retrieved on May 20, 2008]. Retrieved from the Internet: <URL: http://dictionary.reference.com/browse/therapeutic>.
Odeku Oluwatoyin A., Fell, John T.; Effects of the method of preparation on the compression, mechanical, and release properties of Khaya gum matrices; Pharmaceutical development and technology; 2006; vol. 11; 435-436, abstract only.
Peng, Z. et al., “The Mechanical Strength of Bone in Different Rat Models of Experimental Osteoporosis,” Bone 15:523-532, Elsevier Science Ltd. (1994).
Plouffe, L., “Selective Estrogen Receptor Modulators (SERMs) in Clinical Practice,” J. Soc. Gynecol. Investig. 7:S38-S46, Elsevier Science Inc. (Jan.-Feb. 2000).
Porter, Christopher J. H., et al., “Lipid Based Formulations for Oral Administration,” Journal of Receptor & Signal Transduction Research, 21 (2&3) 215-257 (2001).
Qu, Q. et al., “Selective Estrogenic Effects of a Novel Triphenylethylene Compounds, FC1271a, on Bone, Cholesterol Level, and Reproductive Tissues in Intact and Ovariectomized Rats,” Endocrinology 141: 809-820, Association for the Study of Internal Secretions (Feb. 2000).
Quinton Singh, Hiren Patel, Mohamed Cassim; Comparative Evaluations of Tablet Formulations; Rhodes University, School of Pharmaceutical Sciences, Department of Pharmaceutics, Rhodes University, Grahamstown, 6140, RSA; www.ru
Eloranta Maire
Kalapudas Arja
Sodervall Marja
Brinks Hofer Gilson & Lione
Hormos Medical Ltd.
Keys Rosalynd
LandOfFree
Method for the preparation of therapeutically valuable... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the preparation of therapeutically valuable..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the preparation of therapeutically valuable... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4186778